BERLIN (Reuters) – A U.S. proposal to waive patent protection for COVID-19 vaccines would have significant implications for production, a German government spokeswoman said on Thursday, adding the main factors are capacity and quality standards rather than patents.
“The protection of intellectual property is a source of innovation and must remain so in the future,” the spokeswoman said in a statement.
(Reporting by Andreas Rinke; Writing by Madeline Chambers; Editing by Douglas Busvine)
